S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
NASDAQ:CTKB

Cytek Biosciences - CTKB Stock Forecast, Price & News

$8.75
-0.05 (-0.57%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.72
$9.03
50-Day Range
$8.75
$13.47
52-Week Range
$7.38
$16.05
Volume
726,365 shs
Average Volume
709,617 shs
Market Capitalization
$1.19 billion
P/E Ratio
437.72
Dividend Yield
N/A
Price Target
$14.33

Cytek Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
63.8% Upside
$14.33 Price Target
Short Interest
Bearish
5.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.51mentions of Cytek Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.40 M Sold Last Quarter
Proj. Earnings Growth
133.33%
From $0.12 to $0.28 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

652nd out of 989 stocks

Analytical Instruments Industry

21st out of 28 stocks


CTKB stock logo

About Cytek Biosciences (NASDAQ:CTKB) Stock

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CTKB Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
CTKB Cytek Biosciences, Inc.
Cytek Biosciences Down 11% on $46.5M Acquisition Plans
Cytek® Biosciences Introduces Cytek Cloud
See More Headlines
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CTKB Company Calendar

Last Earnings
8/10/2022
Today
3/23/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTKB
Fax
N/A
Employees
496
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.33
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+63.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$2.58 million
Pretax Margin
0.77%

Debt

Sales & Book Value

Annual Sales
$164.04 million
Cash Flow
$0.07 per share
Book Value
$3.16 per share

Miscellaneous

Free Float
113,897,000
Market Cap
$1.19 billion
Optionable
Not Optionable
Beta
0.30

Key Executives

  • Dr. Wenbin Jiang Ph.D. (Age 59)
    Pres, CEO & Chairman
    Comp: $568.5k
  • Mr. Patrik Sebastian Jeanmonod (Age 57)
    Chief Financial Officer
    Comp: $412.54k
  • Dr. Ming Yan Ph.D. (Age 60)
    CTO & Director
    Comp: $514.78k
  • Dr. Allen B. Poirson Ph.D. (Age 63)
    Sr. VP of Bus. & Corp. Devel.
  • Mr. Chris Williams
    Chief Operating Officer
  • Mr. Mark Edinger
    VP of Scientific Affairs
  • Mr. Paul D. Goodson
    Head of Investor Relations
  • Ms. Valerie T. Barnett J.D. (Age 48)
    Gen. Counsel & Corp. Sec.
  • Ms. Connie Wedel
    Chief People Officer
  • Mr. Todd Garland
    Chief Commercial Officer













CTKB Stock - Frequently Asked Questions

Should I buy or sell Cytek Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTKB shares.
View CTKB analyst ratings
or view top-rated stocks.

What is Cytek Biosciences' stock price forecast for 2023?

3 brokers have issued 12 month price targets for Cytek Biosciences' stock. Their CTKB share price forecasts range from $14.00 to $15.00. On average, they predict the company's share price to reach $14.33 in the next year. This suggests a possible upside of 63.8% from the stock's current price.
View analysts price targets for CTKB
or view top-rated stocks among Wall Street analysts.

How have CTKB shares performed in 2023?

Cytek Biosciences' stock was trading at $10.21 at the beginning of 2023. Since then, CTKB stock has decreased by 14.3% and is now trading at $8.75.
View the best growth stocks for 2023 here
.

When is Cytek Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our CTKB earnings forecast
.

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings results on Wednesday, August, 10th. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.01. The company had revenue of $40.16 million for the quarter, compared to analyst estimates of $41.34 million. Cytek Biosciences had a net margin of 1.69% and a trailing twelve-month return on equity of 0.98%.

What guidance has Cytek Biosciences issued on next quarter's earnings?

Cytek Biosciences issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $225.00 million-$235.00 million, compared to the consensus revenue estimate of $214.66 million.

When did Cytek Biosciences IPO?

(CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share.

What is Cytek Biosciences' stock symbol?

Cytek Biosciences trades on the NASDAQ under the ticker symbol "CTKB."

Who are Cytek Biosciences' major shareholders?

Cytek Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.32%), Macquarie Group Ltd. (0.78%), New York State Common Retirement Fund (0.61%), Point72 Asset Management L.P. (0.60%), Miura Global Management LLC (0.58%) and Charles Schwab Investment Management Inc. (0.50%). Insiders that own company stock include Jack Ball, Ming Yan, Patrik Jeanmonod, Ra Capital Management, LP and Wenbin Jiang.
View institutional ownership trends
.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytek Biosciences' stock price today?

One share of CTKB stock can currently be purchased for approximately $8.75.

How much money does Cytek Biosciences make?

Cytek Biosciences (NASDAQ:CTKB) has a market capitalization of $1.19 billion and generates $164.04 million in revenue each year. The company earns $2.58 million in net income (profit) each year or $0.02 on an earnings per share basis.

How many employees does Cytek Biosciences have?

The company employs 496 workers across the globe.

How can I contact Cytek Biosciences?

The official website for the company is www.cytekdev.com. The company can be reached via phone at 877-922-9835 or via email at investors@cytekbio.com.

This page (NASDAQ:CTKB) was last updated on 3/24/2023 by MarketBeat.com Staff